Safety and Efficacy Oral Cholera Vaccine (OCV) in Hodeidah, Yemen
DOI:
https://doi.org/10.59846/ajbas.v4i1.838Abstract
Background : A national Oral Cholera Vaccine (OCV) campaign was launched in Hodeidah, in response to the first outbreak in Hodeidah ,Yemen , May 2017. Objectives: Therefore. the study aimed to monitor the efficacy and determine the incidence of adverse events following immunization (AEFI) with OCV among the Hali District , Hodeidah peoples of Yemen. .
Methodology: The study was designed in two phases, the phase I, a cross sectional survey was designed to monitor the safety (AEFI) of OCV where the study was carried out between 6th May 2018 and 30th August 2018. The study included 210 participants that were administrated the vaccine orally. The adverse events were reported after 24 – 72 hours from administration of vaccine. The phase II , a cohort study was designed after three months of OCV vaccination campaign that included 151 cholera patients in diarrhea treatment center (DTC) with reporting of vaccination status and vaccine efficacy (VE) of OCV was measured based on two methods , the first was rapid measurement method and the second was cohort study . Results: A total of 210, 40 % of males and 60 % of females, aged from 10 years to 60 years. 50 % of participants was children , 30 % of young and 20 % of elderly. The incidence of AEFI of OCV among participants was reported in 20 participants (9.52 %). While, non-serious were reported in 190 participants (90.48 %). The major adverse events were reported as the following: loss appetite (9.52%), vomiting (7.14%), diarrhea (4.29%), abdominal pain (1.92%), and fever (0%). On the other hand, the VE of OCV was 96.72% according to rapid estimation method and 98.65 % based on cohort study. Conclusion: Our findings concluded that OCV was highly safe and effective. Additionally, monitoring AEFIs during emergency cholera outbreak campaigns supports the favorable safety profile of OCV.
References
1. Al Sheebani, S.; Al-Kamarany, M.A.; Ghouth, A.B.; Kamal, A.; Alaq, M . .(2018). Acute renal failure induced by cholera: Outbreak of Hodeidah, Yemen, 2017: European Journal of Pharmaceutical and Medical Research , 5(8), 188–192. https://www.ejpmr.com/home/abstract_id/4065
2. Al-Mekhlafi H. M. (2018). Yemen in a Time of Cholera: Cur-rent Situation and Challenges. The American journal of tropi-cal medicine and hygiene, 98(6), 1558–1562. https://doi.org/10.4269/ajtmh.17-0811
3. Federspiel, F., & Ali, M. (2018). The cholera outbreak in Yemen: lessons learned and way forward. BMC public health, 18(1), 1338. https://doi.org/10.1186/s12889-018-6227-6
4. Lam, E., Al-Tamimi, W., Russell, S. P., Butt, M. O., Blanton, C., Musani, A. S., & Date, K. (2017). Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015. Emerging infectious diseases, 23(1), 38–45. https://doi.org/10.3201/eid2301.160881
5. Berjaoui, C., Akoum, N. A., El Nouiri, A., Khayat, S., Abbass, M., Mousawi, A. A., Wellington, J., & Uwishema, O. (2023). A minireview of cholera outbreak in Lebanon - a rising public health concern. Annals of medicine and surgery (2012), 85(4), 879–883. https://doi.org/10.1097/MS9.0000000000000293
6. Mohamed, N. S., Ali, Y., Abdalrahman, S., Ahmed, A., & Siddig, E. E. (2022). The use of cholera oral vaccine for con-tainment of the 2019 disease outbreak in Sudan. Transac-tions of the Royal Society of Tropical Medicine and Hygiene, 116(9), 763–766. https://doi.org/10.1093/trstmh/trac041
7. Mogasale, V., Kanungo, S., Pati, S., Lynch, J., & Dutta, S. (2020). The history of OCV in India and barriers remaining to programmatic introduction. Vaccine, 38 Suppl 1, A41–A45. https://doi.org/10.1016/j.vaccine.2020.01.016
8. Sinclair, D., Abba, K., Zaman, K., Qadri, F., & Graves, P. M. (2011). Oral vaccines for preventing cholera. The Cochrane database of systematic reviews, 2011(3), CD008603. https://doi.org/10.1002/14651858.CD008603.pub2
9. Song, K. R., Lim, J. K., Park, S. E., Saluja, T., Cho, S. I., Wartel, T. A., & Lynch, J. (2021). Oral Cholera Vaccine Effi-cacy and Effectiveness. Vaccines, 9(12), 1482. https://doi.org/10.3390/vaccines9121482
10. Al Kamarany, M. ., & Ghouth, A. S. B. . (2024). The Ice Berge of Cholera in Hodeidah , Yemen : The Contact Expo-sure. Studies in Medical and Health Sciences, 1(1), 32–35. https://doi.org/10.48185/smhs.v1i1.1169
11. Saif-Ur-Rahman, K. M., Mamun, R., Hasan, M., Meiring, J. E., & Khan, M. A. (2024). Oral killed cholera vaccines for preventing cholera. The Cochrane database of systematic re-views, 1(1), CD014573. https://doi.org/10.1002/14651858.CD014573
12. Fournier, J. M., & Quilici, M. L. (2007). Choléra [Cholera]. Presse medicale (Paris, France : 1983), 36(4 Pt 2), 727–739. https://doi.org/10.1016/j.lpm.2006.11.029
13. Shaikh, H., Lynch, J., Kim, J., & Excler, J. L. (2020). Cur-rent and future cholera vaccines. Vaccine, 38 Suppl 1, A118–A126. https://doi.org/10.1016/j.vaccine.2019.12.011
14. Song, K. R., Chapagain, R. H., Tamrakar, D., Shrestha, R., Kanodia, P., Chaudhary, S., Wartel, T. A., Yang, J. S., Kim, D. R., Lee, J., Park, E. L., Cho, H., Lee, J., Thaisrivichai, P., Vemula, S., Kim, B. M., Gupta, B., Saluja, T., Pansuriya, R. K., Ganapathy, R., … Lynch, J. A. (2024). Safety and immu-nogenicity of the Euvichol-S oral cholera vaccine for preven-tion of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. The Lancet. Global health, 12(5), e826–e837. https://doi.org/10.1016/S2214-109X(24)00059-7
15. Casey, R. M., Najjengo, M. S., Lubega, I., Sekiziyivu, A. B., Twinomuhwezi-Oyet, E., Nakato, W. N., Sciarratta, C. N., Chu, S. Y., Doshi, R. H., Kambugu, A., & Gidudu, J. F. (2024). Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine com-pared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report. Vaccine, 42(22), 126197. https://doi.org/10.1016/j.vaccine.2024.126197
16. Tozzi, A. E., Asturias, E. J., Balakrishnan, M. R., Halsey, N. A., Law, B., & Zuber, P. L. (2013). Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine, 31(44), 5041–5046. https://doi.org/10.1016/j.vaccine.2013.08.087
17. Médecins Sans Frontières (MSF). (2025). MSF medical guidelines . 7.6 Vaccine effectiveness https://medicalguidelines.msf.org/en/viewport/mme/english/7-6-vaccine-effectiveness-32408146.html
18. World Health Organization (WHO). 2019 . Cholera in Yem-en. 6th Annual Meeting , Global Task Force on Cholera Con-trol 3-4 June 2019 https://www.fondation-merieux.org/wp-content/uploads/2018/10/6th-annual-meeting-gtfcc-yemen.pdf
19. Zeitoun, A., Ibrahim, A., Reda El Sayed, S., Hobeika, E., & Karam, R. (2024). Descriptive analysis of adverse events fol-lowing immunization with oral cholera vaccine in Lebanon. Frontiers in public health, 12, 1480744. https://doi.org/10.3389/fpubh.2024.1480744
20. Lam, E., Al-Tamimi, W., Russell, S. P., Butt, M. O., Blanton, C., Musani, A. S., & Date, K. (2017). Oral Cholera Vaccine Coverage during an Outbreak and Humanitarian Crisis, Iraq, 2015. Emerging infectious diseases, 23(1), 38–45. https://doi.org/10.3201/eid2301.160881
21. Song, K. R., Chapagain, R. H., Tamrakar, D., Shrestha, R., Kanodia, P., Chaudhary, S., Wartel, T. A., Yang, J. S., Kim, D. R., Lee, J., Park, E. L., Cho, H., Lee, J., Thaisrivichai, P., Vemula, S., Kim, B. M., Gupta, B., Saluja, T., Pansuriya, R. K., Ganapathy, R., … Lynch, J. A. (2024). Safety and immu-nogenicity of the Euvichol-S oral cholera vaccine for preven-tion of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. The Lancet. Global health, 12(5), e826–e837. https://doi.org/10.1016/S2214-109X(24)00059-7
22. Baik, Y. O., Choi, S. K., Olveda, R. M., Espos, R. A., Ligsay, A. D., Montellano, M. B., Yeam, J. S., Yang, J. S., Park, J. Y., Kim, D. R., Desai, S. N., Singh, A. P., Kim, I. Y., Kim, C. W., & Park, S. N. (2015). A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vac-cines (Euvichol vs Shanchol) in the Philippines. Vaccine, 33(46), 6360–6365. https://doi.org/10.1016/j.vaccine.2015.08.075
23. Wierzba T. F. (2019). Oral cholera vaccines and their impact on the global burden of disease. Human vaccines & immuno-therapeutics, 15(6), 1294–1301. https://doi.org/10.1080/21645515.2018.1504155
24. Deen, J., & Clemens, J. D. (2021). Licensed and Recom-mended Inactivated Oral Cholera Vaccines: From Develop-ment to Innovative Deployment. Tropical medicine and in-fectious disease, 6(1), 32. https://doi.org/10.3390/tropicalmed6010032
25. U.S. Centers for Disease Control and Prevention (CDC). (2025). Cholera Vaccines https://www.cdc.gov/cholera/prevention/cholera-vaccines.html
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mohammed Amood Al Kamarany
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in Abhath Journal of Basic and Applied Sciences (AJOBAS) are open-access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to freely share, copy, distribute, and adapt the work, provided that the original author(s) and source are properly credited.
